Kava
•Last Updated: September 28 2022
Kava is a herb that has traditionally been drunk as a hypnotic and anxiety reducer. It has been shown effective in reducing anxiety, sometimes at a potency similar to pharmaceuticals; may be a cognitive enhancer, but not completely safe.
Kava is most often used for
Last Updated: September 28 2022
Note that Kava is also known as:
- Piper methysticum
- Kava Pepper
- Ava Pepper
- Kava Kava
- Intoxicating Pepper
- Awa
- rauschpfeffer
- sakau
- tonga
- wurzelstock
- yangona
When supplementing Kava, initially an extract known as WS1490 should be sought out. 300mg of this extract daily (in three divided doses of 100mg) appears to be reliable and effective for the treatment of anxiety and other cognitive issues. Doses of up to 800mg of the WS1490 extract have been tolerated for short periods of time.
Otherwise, supplementation of any product conferring 250mg collective kavalactones (the active ingredients) is used.
Although it is usually taken at multiple times throughout the day with meals, if a single dose per day is being used it tends to be used prior to sleep.
What works and what doesn't?
Unlock the full potential of Examine
1.^Ulbricht C, Basch E, Boon H, Ernst E, Hammerness P, Sollars D, Tsourounis C, Woods J, Bent SSafety review of kava (Piper methysticum) by the Natural Standard Research CollaborationExpert Opin Drug Saf.(2005 Jul)
3.^Mathews JD, Riley MD, Fejo L, Munoz E, Milns NR, Gardner ID, Powers JR, Ganygulpa E, Gununuwawuy BJEffects of the heavy usage of kava on physical health: summary of a pilot survey in an aboriginal communityMed J Aust.(1988 Jun 6)
4.^Schelosky L, Raffauf C, Jendroska K, Poewe WKava and dopamine antagonismJ Neurol Neurosurg Psychiatry.(1995 May)
5.^Weiss J, Sauer A, Frank A, Unger MExtracts and kavalactones of Piper methysticum G. Forst (kava-kava) inhibit P-glycoprotein in vitroDrug Metab Dispos.(2005 Nov)
6.^He XG, Lin LZ, Lian LZElectrospray high performance liquid chromatography-mass spectrometry in phytochemical analysis of kava (Piper methysticum) extractPlanta Med.(1997 Feb)
7.^Clayton NP, Yoshizawa K, Kissling GE, Burka LT, Chan PC, Nyska AImmunohistochemical analysis of expressions of hepatic cytochrome P450 in F344 rats following oral treatment with kava extractExp Toxicol Pathol.(2007 Jan)
8.^Baum SS, Hill R, Rommelspacher HEffect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of ratsProg Neuropsychopharmacol Biol Psychiatry.(1998 Oct)
9.^Olsen LR, Grillo MP, Skonberg CConstituents in kava extracts potentially involved in hepatotoxicity: a reviewChem Res Toxicol.(2011 Jul 18)
10.^Whitton PA, Lau A, Salisbury A, Whitehouse J, Evans CSKava lactones and the kava-kava controversyPhytochemistry.(2003 Oct)
12.^Garrett KM, Basmadjian G, Khan IA, Schaneberg BT, Seale TWExtracts of kava (Piper methysticum) induce acute anxiolytic-like behavioral changes in micePsychopharmacology (Berl).(2003 Oct)
13.^Keledjian J, Duffield PH, Jamieson DD, Lidgard RO, Duffield AMUptake into mouse brain of four compounds present in the psychoactive beverage kavaJ Pharm Sci.(1988 Dec)
14.^Thompson R, Ruch W, Hasenöhrl RUEnhanced cognitive performance and cheerful mood by standardized extracts of Piper methysticum (Kava-kava)Hum Psychopharmacol.(2004 Jun)
15.^Duffield AM, Jamieson DD, Lidgard RO, Duffield PH, Bourne DJIdentification of some human urinary metabolites of the intoxicating beverage kavaJ Chromatogr.(1989 Jul 28)
16.^Rasmussen AK, Scheline RR, Solheim E, Hänsel RMetabolism of some kava pyrones in the ratXenobiotica.(1979 Jan)
17.^Zou L, Harkey MR, Henderson GLSynthesis, in vitro, reactivity, and identification of 6-phenyl-3-hexen-2-one in human urine after kava-kava (Piper methysticum) ingestionPlanta Med.(2005 Feb)
18.^Mulholland PJ, Prendergast MAPost-insult exposure to (+/-) kavain potentiates N-methyl-D-aspartate toxicity in the developing hippocampusBrain Res.(2002 Jul 26)
19.^Davies LP, Drew CA, Duffield P, Johnston GA, Jamieson DDKava pyrones and resin: studies on GABAA, GABAB and benzodiazepine binding sites in rodent brainPharmacol Toxicol.(1992 Aug)
20.^Jussofie A, Schmiz A, Hiemke CKavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brainPsychopharmacology (Berl).(1994 Dec)
21.^Serdarevic N, Eckert GP, Müller WEThe effects of extracts from St. John's Wort and Kava Kava on brain neurotransmitter levels in the mousePharmacopsychiatry.(2001 Jul)
22.^Dinh LD, Simmen U, Bueter KB, Bueter B, Lundstrom K, Schaffner WInteraction of various Piper methysticum cultivars with CNS receptors in vitroPlanta Med.(2001 Jun)
23.^Backhauss C, Krieglstein JExtract of kava (Piper methysticum) and its methysticin constituents protect brain tissue against ischemic damage in rodentsEur J Pharmacol.(1992 May 14)
24.^Cropley M, Cave Z, Ellis J, Middleton RWEffect of kava and valerian on human physiological and psychological responses to mental stress assessed under laboratory conditionsPhytother Res.(2002 Feb)
25.^Münte TF, Heinze HJ, Matzke M, Steitz JEffects of oxazepam and an extract of kava roots (Piper methysticum) on event-related potentials in a word recognition taskNeuropsychobiology.(1993)
26.^Scherer JKava-kava extract in anxiety disorders: an outpatient observational studyAdv Ther.(1998 Jul-Aug)
27.^Malsch U, Kieser MEfficacy of kava-kava in the treatment of non-psychotic anxiety, following pretreatment with benzodiazepinesPsychopharmacology (Berl).(2001 Sep)
28.^Boerner RJ, Sommer H, Berger W, Kuhn U, Schmidt U, Mannel MKava-Kava extract LI 150 is as effective as Opipramol and Buspirone in Generalised Anxiety Disorder--an 8-week randomized, double-blind multi-centre clinical trial in 129 out-patientsPhytomedicine.(2003)
30.^Sarris J, Kavanagh DJ, Deed G, Bone KMSt. John's wort and Kava in treating major depressive disorder with comorbid anxiety: a randomised double-blind placebo-controlled pilot trialHum Psychopharmacol.(2009 Jan)
31.^Connor KM, Payne V, Davidson JRKava in generalized anxiety disorder: three placebo-controlled trialsInt Clin Psychopharmacol.(2006 Sep)
32.^Jacobs BP, Bent S, Tice JA, Blackwell T, Cummings SRAn internet-based randomized, placebo-controlled trial of kava and valerian for anxiety and insomniaMedicine (Baltimore).(2005 Jul)
33.^Cairney S, Clough AR, Maruff P, Collie A, Currie BJ, Currie JSaccade and cognitive function in chronic kava usersNeuropsychopharmacology.(2003 Feb)
34.^Cairney S, Maruff P, Clough AR, Collie A, Currie J, Currie BJSaccade and cognitive impairment associated with kava intoxicationHum Psychopharmacol.(2003 Oct)
35.^Spillane PK, Fisher DA, Currie BJNeurological manifestations of kava intoxicationMed J Aust.(1997 Aug 4)
36.^Robinson V, Bergfeld WF, Belsito DV, Klaassen CD, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW; Cosmetic Ingredient Review Expert Panel, Andersen FAFinal report on the safety assessment of Piper methysticum leaf/root/stem extract and Piper methysticum root extractInt J Toxicol.(2009 Nov-Dec)
37.^Herberg KWEffect of Kava-Special Extract WS 1490 combined with ethyl alcohol on safety-relevant performance parametersBlutalkohol.(1993 Mar)
38.^Foo H, Lemon JAcute effects of kava, alone or in combination with alcohol, on subjective measures of impairment and intoxication and on cognitive performanceDrug Alcohol Rev.(1997 Jun)
39.^Jamieson DD, Duffield PHPositive interaction of ethanol and kava resin in miceClin Exp Pharmacol Physiol.(1990 Jul)
40.^Mathews JM, Etheridge AS, Valentine JL, Black SR, Coleman DP, Patel P, So J, Burka LTPharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones in vivo and in vitroDrug Metab Dispos.(2005 Oct)
41.^Schulze J, Raasch W, Siegers CPToxicity of kava pyrones, drug safety and precautions--a case studyPhytomedicine.(2003)
42.^Sarris J, Kavanagh DJ, Byrne G, Bone KM, Adams J, Deed GThe Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticumPsychopharmacology (Berl).(2009 Aug)
45.^Humberston CL, Akhtar J, Krenzelok EPAcute hepatitis induced by kava kavaJ Toxicol Clin Toxicol.(2003)
46.^Gow PJ, Connelly NJ, Hill RL, Crowley P, Angus PWFatal fulminant hepatic failure induced by a natural therapy containing kavaMed J Aust.(2003 May 5)
47.^Sorrentino L, Capasso A, Schmidt MSafety of ethanolic kava extract: Results of a study of chronic toxicity in ratsPhytomedicine.(2006 Sep)
48.^Singh YN, Devkota AKAqueous kava extracts do not affect liver function tests in ratsPlanta Med.(2003 Jun)
49.^Clough AR, Jacups SP, Wang Z, Burns CB, Bailie RS, Cairney SJ, Collie A, Guyula T, McDonald SP, Currie BJHealth effects of kava use in an eastern Arnhem Land Aboriginal communityIntern Med J.(2003 Aug)
50.^Guro-Razuman S, Anand P, Hu Q, Mir RDermatomyositis-like illness following kava-kava ingestionJ Clin Rheumatol.(1999 Dec)
54.^Mathews JM, Etheridge AS, Black SRInhibition of human cytochrome P450 activities by kava extract and kavalactonesDrug Metab Dispos.(2002 Nov)
55.^Zou L, Henderson GL, Harkey MR, Sakai Y, Li AEffects of kava (Kava-kava, 'Awa, Yaqona, Piper methysticum) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytesPhytomedicine.(2004)
56.^Unger M, Holzgrabe U, Jacobsen W, Cummins C, Benet LZInhibition of cytochrome P450 3A4 by extracts and kavalactones of Piper methysticum (Kava-Kava)Planta Med.(2002 Dec)
57.^Gurley BJ, Swain A, Hubbard MA, Hartsfield F, Thaden J, Williams DK, Gentry WB, Tong YSupplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivoClin Pharmacol Ther.(2008 Jan)
58.^Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans.()
59.^Pittler MH, Ernst EEfficacy of kava extract for treating anxiety: systematic review and meta-analysisJ Clin Psychopharmacol.(2000 Feb)
60.^Hsu SY, Lin MH, Lin LC, Chou CJToxicologic studies of dihydro-5,6-dehydrokawain and 5,6-dehydrokawainPlanta Med.(1994 Feb)
Primary Use